Prognostic and diagnostic value of elevated serum concentration of procalcitonin in patients with suspected heart failure. A review and meta-analysis

References

• Alba, G.A., et al., 2015. Diagnostic and prognostic utility of procalcitonin in patients presenting to the emergency department with dyspnea. American journal of medicine, 129 (1), 96–104. e7.
   PubMed Web of Science ®Google Scholar
• Brunkhorst, F.M., et al., 1999. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. International journal of cardiology, 72 (1), 3–10.
   PubMed Web of Science ®Google Scholar
• Castelli, G.P., et al., 2004. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Critical care, 8 (4), R234–R242.
   PubMed Web of Science ®Google Scholar
• Christ-Crain, M., et al., 2006. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. American journal of respiratory and critical care medicine, 174 (1), 84–93.
   PubMed Web of Science ®Google Scholar
• Demissei, B.G., et al., 2016. Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. International journal of cardiology, 204, 164–171.
   PubMed Web of Science ®Google Scholar
• Fonarow, G.C., et al., 2008. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Archives of internal medicine, 168 (8), 847–854.
   PubMedGoogle Scholar
• Geppert, A., et al., 2003. Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intensive care medicine, 29 (8), 1384–1389.
   PubMed Web of Science ®Google Scholar
• Hausfater, P., et al., 2002. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clinical infectious diseases, 34 (7), 895–901.
   PubMed Web of Science ®Google Scholar
• Hausfater, P., et al., 2007. Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Critical care, 11 (3), R60.
   PubMed Web of Science ®Google Scholar
• Huang, D.T., et al., 2008. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Annals of emergency medicine, 52 (1), 48–58. e2.
   PubMed Web of Science ®Google Scholar
• Hur, M., et al., 2014. Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis. BMC infectious diseases, 14, 224. doi: 10.1186/1471-2334-14-224
   PubMed Web of Science ®Google Scholar
• Januzzi, J.L. Jr., et al., 2005. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. American journal of cardiology, 95 (8), 948–954.
   PubMed Web of Science ®Google Scholar
• Jensen, J.U., et al., 2008. The Procalcitonin and Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker procalcitonin and pro-active diagnostic and therapeutic responses to abnormal procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. BMC Infectious diseases, 8, 91.
   PubMed Web of Science ®Google Scholar
• Kruger, S., et al., 2008. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. European respiratory journal, 31 (2), 349–355.
   PubMed Web of Science ®Google Scholar
• Liu, D., et al., 2016. Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis. Respirology (Carlton, Vic.), 21 (2), 280–288.
   PubMed Web of Science ®Google Scholar
• Magrini, L., et al., 2014. Comparison between white blood cell count, procalcitonin and C reactive protein as diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to emergency department. Clinical chemistry and laboratory medicine, 52 (10), 1465–1472.
   PubMed Web of Science ®Google Scholar
• Maisel, A., et al., 2012. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. European journal of heart failure, 14 (3), 278–286.
   PubMed Web of Science ®Google Scholar
• Maisel, A.S., and Choudhary, R., 2012. Biomarkers in acute heart failure-state of the art. Nature reviews. Cardiology, 9 (8), 478–490.
   PubMed Web of Science ®Google Scholar
• Mockel, M., et al., 2013. Chief complaints in medical emergencies: do they relate to underlying disease and outcome? The Charite Emergency Medicine Study (CHARITEM). European journal of emergency medicine, 20 (2), 103–108.
   PubMed Web of Science ®Google Scholar
• Moe, G.W., et al., 2007. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation, 115 (24), 3103–3110.
   PubMed Web of Science ®Google Scholar
• Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G., 2009. PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine, 6, e1000097.
   PubMed Web of Science ®Google Scholar
• Muller, B., et al., 2007. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC infectious diseases, 7, 10.
   PubMed Web of Science ®Google Scholar
• Ponikowski, P., et al., 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal, 37 (27), 2129–2200.
   PubMed Web of Science ®Google Scholar
• Schuetz, P., et al., 2007. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC health services research, 7, 102.
   PubMed Web of Science ®Google Scholar
• Schuetz, P., et al., 2011. Prognostic value of procalcitonin in community-acquired pneumonia. The European respiratory journal, 37 (2), 384–392.
   PubMed Web of Science ®Google Scholar
• Schuetz, P., et al., 2014. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. International journal of cardiology, 175 (3), 464–472.
   PubMed Web of Science ®Google Scholar
• Teboul, A., et al., 2004. Management of acute dyspnoea: use and feasibility of brain natriuretic peptide (BNP) assay in the prehospital setting. Resuscitation, 61 (1), 91–96.
   PubMed Web of Science ®Google Scholar
• Travaglino, F., et al., 2014. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial. American journal of emergency medicine, 32 (4), 334–341.
   PubMed Web of Science ®Google Scholar
• Viechtbauer, W., 2010. Conducting meta-analyses in R with the metafor package. Journal of statistical software , 36, 1–48.
   Web of Science ®Google Scholar
• Villanueva, M.P., et al., 2015. Procalcitonin and long-term prognosis after an admission for acute heart failure. European journal of internal medicine, 26 (1), 42–48.
   PubMed Web of Science ®Google Scholar
• Wang, W., et al., 2014. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4698 cases. Critical care, 18 (1), R4.
   PubMed Web of Science ®Google Scholar